Nutra Pharma Corp. Announces Final Approval To Begin Phase IIb Human Clinical Trial For The Treatment Of Adrenomyeloneuropathy

BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that ReceptoPharm, has received Ethics Committee approval in the UK to begin its Phase IIb human clinical trial for the treatment of Adrenomyeloneuropathy (AMN). ReceptoPharm, the drug-discovery holding of Nutra Pharma, is currently studying the effectiveness of Cobra Venom and Cobratoxin as treatments for Multiple Sclerosis, HIV, Adrenomyeloneuropathy (AMN), Pain and Rabies.